3-氨基-1-苯基-1H-吡唑-4-羧酸乙酯 | 16078-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氨基-1-苯基-1H-吡唑-4-羧酸乙酯
• 中文别名: 3-氨基-1-苯基-1H-吡唑-4-甲酸乙酯
• 英文名称: 3-amino-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester
• 英文别名: ethyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate；3-amino-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester；ethyl 3-amino-1-phenyl-lH-pyrazole-4-carboxylate；1-Phenyl-3-amino-4-aethoxycarbonyl-pyrazol；ethyl 3-amino-1-phenylpyrazole-4-carboxylate
• CAS: 16078-63-0
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: WATKLRBOWCFWFU-UHFFFAOYSA-N

物化性质

• 沸点：
  385.1±22.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933199090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-氨基-1-苯基-1H-吡唑-4-羧酸乙酯 在 氢溴酸 、 copper(I) bromide 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 3.0h， 生成 ethyl 3-bromo-1-phenyl-1H-pyrazole-4-carboxylate
  参考文献：
  名称：

  [EN] HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE
  [FR] INHIBITEURS HÉTÉRO-HALOGÉNO D'HISTONE DÉSACÉTYLASE

  摘要：

  这项发明提供了抑制HDAC2的化合物。这些化合物（例如，符合式I、II或化合物100-128中的任何一种，或表2或3中的任何一种）可用于治疗、缓解或预防受试者的疾病，如神经系统疾病、记忆或认知功能障碍或损伤、消退学习障碍、真菌疾病或感染、炎症性疾病、血液疾病或肿瘤性疾病，或用于改善记忆或治疗、缓解或预防记忆丧失或损伤。

  公开号：

  WO2017007756A1
• 作为产物：
  描述：

  2-氰基-3-乙氧基丙烯酸乙酯 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 potassium phosphate 、 copper(l) iodide 、 一水合肼 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 54.0h， 生成 3-氨基-1-苯基-1H-吡唑-4-羧酸乙酯
  参考文献：
  名称：

  Application of Ullmann and Ullmann–Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation

  摘要：

  Ullmann-type reactions are becoming a major tool in medicinal chemistry. In this article, we describe the use of these Copper-catalyzed reactions with various precursors, acyl-heteroarylamines or pyrazoles of interest for pharmacomodulation. To the medicinal chemist they offer new, usually untapped disconnection approaches to compounds of interest. They thus open the way to new original analogues of bioactive compounds possibly not patented, from common building-blocks. They also allow C to N bioisosteric replacements, which sometimes are synthetically challenging. We report for the first time the critical effect of acetylamino substituents on the regioselective arylation of unsymmetrical pyrazoles that are useful for medicinal chemists. Finally, we have applied this strategy to the design of novel AT, receptor antagonists. Though this family has been extensively investigated in the past 30 years, N-arylation and C to N replacement made possible by Ullmann chemistry, can produce original antagonists. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.05.056

文献信息

• FIVE-MEMBERED HETEROCYCLIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1541564A1

  公开（公告）日：2005-06-15

  The present invention provides a compound represented by the formula: wherein R1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- or -Z1-(CH2)n- (n is an integer of 0 to 8, Z1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R2 is a hydrogen atom, a cyano group, -PO(OR9)(OR10) (R9 and R10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R9 and R10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供了一种由以下式表示的化合物： 其中R1是可选择地取代的5-成员杂环基团；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q是具有1到20个碳原子的二价碳氢基团；环A是一个芳香环，可选择地进一步具有1到3个取代基；Z是-(CH2)n-Z1-或-Z1-(CH2)n-（n是0到8的整数，Z1是键，氧原子，硫原子等）；环B是一个含氮杂环，可选择地进一步具有1到3个取代基；W是键或具有1到20个碳原子的二价碳氢基团；R2是氢原子，氰基，-PO(OR9)(OR10)（R9和R10相同或不同，每个是氢原子或可选择地取代的碳氢基团，R9和R10可选择地结合形成可选择地取代的环）等，或其盐，具有优越的减少脂肪组织重量的作用，降糖作用和降脂作用，并且作为预防或治疗肥胖症，糖尿病，高脂血症，糖耐量受损，高血压等的药剂是有用的。
• [EN] 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS<br/>[FR] DÉRIVÉS DE 4-CARBOX PYRAZOLE UTILES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GLAXO GROUP LTD

  公开号：WO2005092863A1

  公开（公告）日：2005-10-06

  Novel antiviral compounds of Formula (I) : wherein: A represents hydroxy; R1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, C1-6alkyl or -C5-9cycloalkyl, each of which may be optionally substituted; R2 represents substituted phenyl, or -(CH2)nC5-7cycloalkyl optionally substituted on the cycloalkyl; R3 represents heterocyclyl or heteroaryl; optionally substituted phenyl or optionally substituted -C1-6alkyl; R4 represents hydrogen; and salts, solvates and esters thereof, processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.

  化合物的新型抗病毒化合物的结构式（I）：其中：A代表羟基；R1代表芳基，通过一个环碳原子结合的杂环芳基，或者通过一个环碳原子结合的杂环烷基，C1-6烷基或-C5-9环烷基，每种基团可以选择性地被取代；R2代表取代苯基，或者选择性地被取代的-(CH2)nC5-7环烷基；R3代表杂环烷基或杂环芳基；或者选择性地被取代的苯基或选择性地被取代的-C1-6烷基；R4代表氢；以及它们的盐、溶剂合物和酯，提供了其制备方法、包含它们的药物组合物，以及在HCV治疗中使用它们的方法。
• SPIRO-CYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911753A1

  公开（公告）日：2008-04-16

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中 E是一个可选择地取代的环状基团； D是一个羰基团或磺酰基团； A是CH或N； 环P是一个可选择进一步取代的5至7元环； 环Q是一个可选择进一步取代的5至7元非芳香环； 环R是一个可选择进一步取代和可选择缩合的5至7元非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等的预防或治疗具有用处，并且在功效、持续活性、特异性、低毒性等方面具有优越性能。
• Heteroarenobenzodiazepines. Part 7. Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b] and [4,3-b][1,5]benzodiazepines as potential anxiolytics
  作者：Jiban K. Chakrabarti、Terrence M. Hotten、Ian A. Pullar、Nicholas C. Tye

  DOI：10.1021/jm00132a012

  日期：1989.12

  The synthesis and pharmacological evaluation of a series of pyrazolo[b][1,5]benzodiazepines are described. Some of the 4-piperazinyl-2,10-dihydropyrazolo[3,4-b][1,5]benzodiazepine derivatives demonstrated potent anxiolytic activity in the three-part operant anticonflict test in rats. Compounds 21 and 30 were more active than the clinically effective anxiolytic chlordiazepoxide in releasing conflict-suppressed

  描述了一系列吡唑并[b] [1,5]苯并二氮杂s的合成和药理学评价。在大鼠的三部分操作性抗冲突试验中，一些4-哌嗪基-2,10-二氢吡唑并[3,4-b] [1,5]苯并二氮杂卓衍生物具有较强的抗焦虑活性。化合物21和30在释放冲突抑制行为方面比临床上有效的抗焦虑药氯氮卓更具活性。这项研究表明，分别在噻吩和二苯并二氮杂卓衍生物氟美沙平和氯氮平中发现的抗焦虑和抗多巴胺能活性已解离。描述并评估了其他三个其他二氢吡唑并[b] [1,5]苯并二氮杂ring环系统的实例，发现它们的活性较低。
• A Michael Equilibration Model To Control Site Selectivity in the Condensation toward Aminopyrazoles
  作者：Daniel R. Fandrick、Sanjit Sanyal、Joseph Kaloko、Jason A. Mulder、Yuwen Wang、Ling Wu、Heewon Lee、Frank Roschangar、Matthias Hoffmann、Chris H. Senanayake

  DOI：10.1021/acs.orglett.5b01248

  日期：2015.6.19

  A Michael equilibration model is presented to provide for site-selective pyrazole condensations between alkoxyacrylonitriles and hydrazines. Both pyrazole isomers were accessed with high selectivity by employment of kinetically or thermodynamically controlled conditions. Substrate scope and identification of Michael intermediates, as well as competitive pathways, support the presented mechanistic proposal

  提出了迈克尔平衡模型，以提供烷氧基丙烯腈和肼之间的位点选择性吡唑缩合。通过采用动力学或热力学控制条件，可以高选择性地获得两种吡唑异构体。迈克尔中间体的底物范围和鉴定，以及竞争途径，为提出的机械方案提供了支持。桑德迈尔的衍生化作用提供了对完全取代的吡唑的位置选择的途径。